Posted on 1/5/18
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MALVERN, Pa., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies . . .
Posted on 1/4/18
Johnson & Johnson Presents A Good Investment Case With Tremfya
Johnson & Johnson (JNJ) had a strong 2017 both on and off the stock market. The company stock maintained an upward trend throughout the year. Johnson . . .
Posted on 1/4/18
3 Biotech Stocks to Buy in January
Biotechnology stocks performed exceptionally well last year, and this positive trend appears set to continue in 2018. As such, investors may want to kick off the . . .
Posted on 1/4/18
Helius Medical Technologies Announces Planned Five-for-One Reverse Stock Split
NEWTOWN, Pa., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (TSX:HSM) (TSX:HSM.WT) (OTCQB:HSDT), a medical technology company focused on neurological wellness, announced today that . . .
Posted on 1/3/18
Egalet Partners with OraPharma
Egalet Corporation (Nasdaq: EGLT) (Egalet), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced . . .
Posted on 1/3/18
CytoSorbents To Provide Corporate Update at Biotech Showcase 2018
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around . . .
Posted on 1/3/18
Celgene - Don't Forget The Pipeline
A tale of two halves - 20172017 has been an interesting year for Celgene as a whole. What began in 2017 as a strong bull-run for . . .
Posted on 1/3/18
3 Best Big Pharma Stocks to Buy for 2018
If you're expecting massive revenue growth for 2018 among big pharma stocks, think again. Despite hot new drugs for several major drugmakers, many of them also . . .
Posted on 1/3/18
Inovio Enters License and Collaboration Agreement with ApolloBio
PLYMOUTH MEETING, Pa., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it entered an amended agreement providing ApolloBio Corporation (NEEQ:430187) with . . .
Posted on 1/2/18
Premarket Analyst Action - Healthcare
Odonate Therapeutics (Pending:ODT) initiated with Buy rating and $40 (60% upside) price target by Jefferies. Initiated with Outperform rating by Cowen and Company.Denali Therapeutics (Pending:DNLI) initiated . . .
Posted on 1/2/18
Proposed Combination of Concentra and US HealthWorks Receives Clearance
Select Medical Holdings Corporation (NYSE: SEM) and Dignity Health today announced that the Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino . . .
Posted on 12/31/17
Recro Pharma Reports Inducement Grants for New Staff
MALVERN, Pa., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute . . .
Posted on 12/31/17
Helius Medical Technologies Closes Final Tranche of Private Placement
NEWTOWN, Pa., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (TSX:HSM) (TSX:HSM.WT) (OTCQB:HSDT), a medical technology company focused on neurological wellness, is pleased to . . .
Posted on 12/30/17
Brainstorm Issues 2017 Letter to Shareholders
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to Shareholders from its President . . .
Posted on 12/22/17
Teva's Restructuring Plan
BackgroundKåre Schultz was appointed as Teva’s (NYSE:TEVA) CEO in September 2017 at the time when Teva has been suffering from Copaxone competition, U.S. generics margin erosion . . .
Posted on 12/22/17
Akers Biosciences Announces Closing of $6,900,000 Public Offering
THOROFARE, N.J., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), a developer of rapid health information technologies, today announces the closing . . .
Posted on 12/21/17
Windtree Therapeutics Announces Reverse Stock Split
Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced a 1-for-20 reverse stock split of . . .
Posted on 12/21/17
Aetna Joins SAFE-BioPharma Association
TENAFLY, N.J.--(BUSINESS WIRE)--SAFE-BioPharma Association today announced that Aetna, one of the nation’s leading diversified health care benefits companies, has become its most recent member. It is . . .
Posted on 12/21/17
Ionis Earns $5M Milestone From J&J On Initiation Of Early-Stage Study Of Orally Delivered Antisense Drug For GI Disorders
Ionis Pharmaceuticals (NASDAQ:IONS) initiates a Phase 1 clinical trial assessing its first orally delivered antisense drug, IONIS-JBI1-2.5rx, for the treatment of an unspecified gastrointestinal (GI) immune . . .
Posted on 12/21/17
Pfizer Giving You A Raise
Image creditPfizer (PFE) has long been a strong dividend stock. The big pharma area is littered with companies that pay nice yields. But PFE has made . . .
Posted on 12/21/17
Ortho Clinical Diagnostics Recognized as One of The Economic Times Best Asian Healthcare Brands 2017
Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, has been recognized as one of The Economic Times Best Asian Healthcare Brands for 2017. . . .
Posted on 12/20/17
Teva's Tough Hanukah: Updated Analysis
Introduction: TEVA has an unhappy HanukahWhen you've been a corporate schlemiel, lumps of coal (or the equivalent) may be what you get under the Hanukah bush . . .
Posted on 12/20/17
Why 2017 Was a Year to Remember for Johnson & Johnson
With less than two weeks remaining in 2017, Johnson & Johnson (NYSE:JNJ) is on track to have its second-best year of the century so far for . . .
Posted on 12/20/17
Celgene Shareholders Excited by CAR-T News
At the recent annual American Society of Hematology (ASH) conference, Celgene (NASDAQ:CELG) reported trial results for the multiple myeloma CAR-T drug it's making with bluebird bio . . .
Posted on 12/20/17
Madrigal Pharmaceuticals Prices Public Offering of Common Stock
CONSHOHOCKEN, Pa., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for . . .

